Public preview. Funding rounds, founders, and growth signals require a free account.

Cadrenal Therapeutics, Inc. (CVKD)

Cadrenal Therapeutics is a late-stage biopharmaceutical company developing novel therapies for life-threatening immune and thrombotic conditions. Its lead program, CAD-1005, is a first-in-class 12-LOX inhibitor in phase 3 development for heparin-induced thrombocytopenia, with a pipeline that also includes oral and parenteral anticoagulant candidates for kidney disease and acute care settings.

Series BBiotechPonte Vedra, FL1-10 employees

Total raised

$21.7M

Last round

Option

$4.4M · Dec 2025

Stage

Series B

Status

Active

Founders & team

Co-founder, CEO

Co-founder, CTO

Head of Engineering

Head of Sales

🔒

Sign up to see founders

Free account unlocks founder names, LinkedIn profiles, and prior companies.

Create free account

Growth signals

Web traffic

Search interest

Social followers

Glassdoor rating

News mentions

Gov contracts

🔒

Sign up to see signals

Free account unlocks 5 full profiles per day. Pro removes the limit.

Create free account

Track Cadrenal Therapeutics, Inc. (CVKD) on FlareSight

Get notified the moment Cadrenal Therapeutics, Inc. (CVKD) files a new round, hires execs, or shows traction signals.

Create free account

About this data

FlareSight surfaces funding data from SEC Form D filings within hours of submission. Browse our full startup funding database to find more recently funded companies.